Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
The Fly
Alnylam price target raised to $475 from $405 at Morgan Stanley
8d ago
ALNY
Premium
The Fly
Alnylam price target raised to $495 from $441 at Stifel
8d ago
ALNY
Premium
Company Announcements
Alnylam Pharma Secures $500M Credit Agreement
11d ago
8K
ALNY
Premium
The Fly
Alnylam doses first patient in ZENITH trial
13d ago
ALNY
Premium
The Fly
Alnylam announces results from HELIOS-B Phase 3 study of AMVUTTRA
16d ago
ALNY
Premium
The Fly
Alnylam price target raised to $500 from $435 at RBC Capital
25d ago
ALNY
Premium
The Fly
Alnylam price target raised to $520 from $453 at BofA
27d ago
ALNY
Premium
Ratings
Alnylam Pharma: Promising Growth Driven by ATTR-CM Franchise and siRNA Platform Expansion
27d ago
ALNY
Premium
Company Announcements
Alnylam Pharma Executes Note Repurchase Transactions
1M ago
8K
ALNY
Premium
Company Announcements
Alnylam Pharma Announces $500M Convertible Notes Offering
1M ago
8K
ALNY
Premium
The Fly
Alnylam announces $500M convertible senior notes offering
1M ago
ALNY
Premium
The Fly
Alnylam price target raised to $470 from $450 at BMO Capital
1M ago
ALNY
CHRO
Premium
Ratings
Cautious Hold Rating for Alnylam Pharma Amid Uncertain Efficacy of Zilebesiran in KARDIA-3 Trial
1M ago
ALNY
Premium
The Fly
Alnylam price target raised to $583 from $527 at Citi
1M ago
ALNY
Premium
Ratings
Positive Outlook on Alnylam Pharma’s Hypertension and ATTR-CM Developments
1M ago
ALNY
Premium
Ratings
Cautious Hold Rating on Alnylam Pharma Amid Promising Yet Inconclusive Zilebesiran Trial Results
1M ago
ALNY
Premium
Ratings
Buy Rating for Alnylam Pharma Driven by Promising Zilebesiran Developments and Strategic Partnership with Roche
1M ago
ALNY
Premium
Ratings
Positive Outlook on Alnylam Pharma: Buy Rating Backed by Zilebesiran’s Potential and Amvuttra’s Market Opportunity
1M ago
ALNY
Premium
Ratings
Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic Partnerships
1M ago
ALNY
Premium
The Fly
Alnylam reports new data from HELIOS-B Phase 3 study
1M ago
ALNY
Premium
The Fly
Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran
1M ago
ALNY
CHRO
Premium
The Fly
Alnylam price target raised to $570 from $500 at H.C. Wainwright
2M ago
ALNY
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
